Literature DB >> 30955976

Pembrolizumab for all PD-L1-positive NSCLC.

Egbert F Smit1, Adrianus J de Langen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30955976     DOI： 10.1016/S0140-6736(18)32559-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?

Authors:  Yiqing Huang; Robert J Walsh; Ross A Soo
Journal:  Transl Lung Cancer Res       Date:  2019-10

2.  A Problematic Biomarker Trial Design.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2022-02-07       Impact factor: 13.506

Review 3.  Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.

Authors:  Ronald Anderson; Annette J Theron; Bernardo L Rapoport
Journal:  Front Immunol       Date:  2019-09-26       Impact factor: 7.561

4.  EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE®.

Authors:  Konstantinos Sapalidis; Paul Zarogoulidis; Dimitris Petridis; Christoforos Kosmidis; Barbara Fyntanidou; Kosmas Tsakiridis; Elena Maragouli; Aikaterini Amaniti; Dimitris Giannakidis; Charilaos Koulouris; Stylianos Mantalobas; Athanasios Katsaounis; Vyron Alexandrou; Georgios Koimtzis; Efstathios Pavlidis; Anastasios Barmpas; Theodora Tsiouda; Chrysanthi Sardeli; Zoi Aidoni; Haidong Huang; Qiang Li; Wolfgang Hohenforst-Schmidt; Isaak Kesisoglou
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

Review 5.  Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.

Authors:  Stefano Frega; Alessandro Dal Maso; Giulia Pasello; Lea Cuppari; Laura Bonanno; PierFranco Conte; Laura Evangelista
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

6.  ctDNA facilitated the diagnosis of a patient with synchronous urothelial carcinoma and non-small cell lung cancer: case report.

Authors:  Chengyuan Qian; Nan Dai; Mingfang Xu; Hao Luo; Yan Feng; Min Zhang; Rongrong Chen; Dong Wang
Journal:  Ann Transl Med       Date:  2020-10

7.  Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments.

Authors:  S M Castenmiller; R de Groot; A Guislain; K Monkhorst; K J Hartemink; A A F A Veenhof; E F Smit; J B A G Haanen; M C Wolkers
Journal:  Immunooncol Technol       Date:  2022-06-22

8.  Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study.

Authors:  Ya Chen; Yanan Wang; Zhengyu Yang; Minjuan Hu; Yanwei Zhang; Fangfei Qian; Wei Zhang; Bo Zhang; Baohui Han
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

9.  Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

Authors:  Alfonso Fiorelli; Fabiana Vitiello; Floriana Morgillo; Mario Santagata; Chiara Spuntarelli; Marina Di Domenico; Mario Santini; Andrea Bianco
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.